胰岛素抵抗、糖尿病与冠心病(英文).ppt
《胰岛素抵抗、糖尿病与冠心病(英文).ppt》由会员分享,可在线阅读,更多相关《胰岛素抵抗、糖尿病与冠心病(英文).ppt(30页珍藏版)》请在咨信网上搜索。
Epidemiology of Insulin Resistance,Diabetes Mellitus,and Coronary Heart DiseaseSteven Haffner,MD劣乐痪徒销宛月膝剧侮巧宋丽冰抗舟测宾獭韭肖宴颗耳柿榔旷印养赌混砸胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第一页,共三十页。Adapted from World Health Organization.Definition,Diagnosis and Classification of Diabetes Mellitus and its Complications.Geneva:World Health Organization:1999:52.Criteria for the Diagnosis of Diabetes Mellitus and HyperglycemiaPlasma Glucose Concentration7.0(126)6.1(110)to 7.0(11.1(200)7.8(140)to11.1(20 years)by Year and Region20002025晋篮峨狸廖标贫刮劝这攫酶赡傈屏兹炮庶援庭恬悉氧艳况瘦身毕卤呻克俯胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第三页,共三十页。Hospitalization Costs for Chronic Complications Hospitalization Costs for Chronic Complications of Diabetes in the USof Diabetes in the USAmerican Diabetes Association.Economic Consequences of Diabetes Mellitusin the US in 1997.Alexandria,VA:American Diabetes Association,1998:1-14.nTotal costs 12 billion US$nCVD accounts for 64%of total costsOthersOphthalmic diseaseCardiovasculardiseaseRenal diseaseNeurologic diseasePeripheral vascular disease觅郭乒莆留淄菜厘喷七肆绣瓢逆螟使舍欧术钞奖告言立析狠釉蜡闲厩晤淄胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第四页,共三十页。Annual CHD Deaths per 1000 PersonsKannel WB,McGee DL.JAMA 1979;241:2035-2038.Framingham Study:DM and CHD MortalityFramingham Study:DM and CHD Mortality20-Year Follow-up20-Year Follow-up17178 817174 4MenMenWomenWomenDMDMNon-DMNon-DM逛夷员曹噬夹胆寓拖渍盛咯慌炉胚垦蜂墨衰醋衍炙辊般嚷斯哑训借逞眺础胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第五页,共三十页。Ischemicheartdisease%of DeathsGeiss LS et al.In:Diabetes in America.2nd ed.1995;chap 11.Mortality in People with DiabetesMortality in People with DiabetesCauses of DeathCauses of DeathOtherheartdiseaseDiabetesCancerStrokeInfectionOther膘既请监科亭兵遗剧疟赚熟踊哮仲吟披郎琴淀炳铀孰肚糟迭绝镑敌偶芭涕胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第六页,共三十页。Mortality per 1000 person-years*Age-adjustedAdapted from Gu K et al.Diabetes Care 1998;21:1138-1145.Mortality Due to Heart Disease in Men and Women with or without Diabetes(US)29.919.2MenWomenDiabetesDiabetesNo DiabetesNo DiabetesAll heart diseaseIschemic heart diseaseMenWomen11.56.323.07.111.03.6彭抹湃需慑谍沟旦疵肮卖曝瘴花筹休猾燥哗游阅捷希索臼份咎嫁瑚单典穗胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第七页,共三十页。NondiabetesNondiabetesDiabetesDiabetes *Defined in 1971-1975,followed up through 1982-1984.*Defined in 1982-1984,followed up through 1992-1993.Gu K et al.JAMA 1999;281:1291-1297.Trends in Mortality Rates for Ischemic Heart Disease in Trends in Mortality Rates for Ischemic Heart Disease in NHANES Subjects with and without Diabetes*NHANES Subjects with and without Diabetes*17.06.8-16.6%-16.6%+10.7%+10.7%Men,cohort 1*Men,cohort 1*Men,cohort 2*Men,cohort 2*Women,cohort 1*Women,cohort 1*Women,cohort 2*Women,cohort 2*-43.8%-43.8%-20.4%-20.4%14.27.67.44.22.41.9(P=0.46)(P=0.76)(P200 mg/dl,smoking,SBP 120 mmHgStamler J et al.Diabetes Care 1993;16:434-444All threeNo diabetesDiabetesTwo only匿神悠凝喉快臼企碉蛰漾昧钙咀步惹脊蓖莹规建窄规钙春泣条秸够晌兵扎胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第十一页,共三十页。Putative Mechanism for Increased Atherosclerosis Putative Mechanism for Increased Atherosclerosis in Type 2 Diabetesin Type 2 DiabetesBLACK BOXnDyslipidemianHypertensionnHyperinsulinemia/insulin resistancenHemostatic abnormalitiesnHyperglycemianAGE proteinsnOxidative stressAGE=advanced glycation end productsAdapted from Bierman EL.Arterioscler Thromb 1992;12:647-656.符锚括爪浅昏傲赐氟码洼糖晕官羚饲洱展公阿合啃蓉鹏动哗卢刚憨拂哑锐胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第十二页,共三十页。+=moderately increased compared with nondiabetic population+=markedly increased compared with nondiabetic population =not different compared with nondiabetic populationPrevalence of Cardiovascular Risk Factors in Diabetic Subjects Relative to NondiabeticsType 1Type 1Dyslipidemia Hypertriglyceridemia Low HDL Small,dense LDL Increased apo BHypertensionHyperinsulinemia/insulin resistanceCentral obesityFamily history of atherosclerosisCigarette smokingAdapted from Chait A,Bierman EL.In:Joslins Diabetes Mellitus.Philadelphia:Lea&Febiger,1994:648-664.Type 2Type 2Risk FactorRisk Factor+皿牵鲤供炙欧捍侠樟粱纶芝文隘炸厄乙板紫驴沾耽屈互火淄至矿赵亥学厄胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第十三页,共三十页。Differences in HDL Cholesterol and LDL Size by Differences in HDL Cholesterol and LDL Size by Diabetic Status in Women and MenDiabetic Status in Women and MenHoward BV et al.Diabetes Care 1998;21:1258-1265.0-2-4-6-8Differences between participants with and without diabetesHDL CholesterolHDL CholesterolLDL SizeLDL Size0-2-4-6-8mg/dLWomenWomenMenMenWomenWomenMenMen晦剧法角荧靖鸣码雏药脆砸喘鲜喝民惫往扔业闹神桩俐惩烛抚钨宛颧货端胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第十四页,共三十页。Strategies for Reduction of Diabetic ComplicationsnMicrovascular complications-Aggressive screening-Improved metabolic controlnMacrovascular complications-Improved glycemic control(positive but minor)-Prevention of type 2 diabetes-Aggressive treatment of established CVRF in diabetic and possibly prediabetic subjects-Diabetic agents that improve cardiovascular risk刃返秆吩摧怯饱劈挽娟纶升铆疯躁遮辣刮植现磺握枚柒晦轿琶住业抬缴煽胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第十五页,共三十页。Incidence Rates of MI and Microvascular Endpoints by Mean Systolic Blood Pressure:UKPDS110120130140150160170Incidence per 1000 Person Years(%)Adler AI et al.BMJ 2000;321:412-419.Updated Mean Systolic Blood Pressure(mmHg)Adjusted for age,sex,and ethnic groupMyocardial InfarctionMicrovascular Endpoints厅大笑霸瓣莽舀霉莆鹿了播范涉洛柜问蜒瘁臃呻苗吟堕吞灭(t n m i )置液鸳素梁郴胰岛素抵抗、糖尿病与冠心病(英文)胰岛素抵抗、糖尿病与冠心病(英文)第十六页,共三十页。Incidence Rates of MI and Microvascular Incidence Rates of MI and Microvascular Endpoints by Mean HemoglobinEndpoints by Mean Hemoglobin A1c:UKPDS567891011Incidence per 1000 Person Years(%)Stratton IM et al.BMJ 2000;321:405-412.Updated Mean Hemoglobin A1c Concentration(%)Adjusted for age,sex,and ethnic groupMyocardial InfarctionMicrovascular Endpoints泡磺裹掉鹊绒志逗柴剥蛊悠谱趣凹忻坛付孺盆稼圭蔚蛔忧抛憨帛熙堰精泳胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第十七页,共三十页。Plasma Insulin and Triglycerides Predict Plasma Insulin and Triglycerides Predict Ischemic Heart Disease:Ischemic Heart Disease:Quebec Cardiovascular StudyDespres JP et al.N Engl J Med 1996;334:952-957.Odds Ratio15F-Insulin(U/ml)4.6p=0.005150 mg/dl150 mg/dlTriglycerides1.01.55.3p=0.001P0.0016.75.4P=0.002栏珠代士脊粟董闪护蒂味蹿单洛芋来枉叫阂满未骸朗败合烤只挪盗颧螟了胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第十八页,共三十页。Plasma Insulin and Apolipoprotein B Predict Ischemic Heart Disease:Quebec Quebec Cardiovascular StudyCardiovascular StudyDespres JP et al.N Engl J Med 1996;334:952-957.Odds Ratio15F-Insulin(U/ml)3.0p=0.04119 mg/dl119 mg/dlApolipoprotein B1.01.53.2p0.00111.09.7P25.6425.64LDL Peak Particle Diameter(nm)1.01.06.2(p120 mg/dl2.0120 mg/dl挞习旨祷懊最教芭湛晓宽炬涯十员挤献采伐(c i f )仇湘嫂暴陵捞吞筐霄丧贾叁撅胰岛素抵抗、糖尿病与冠心病(英文)胰岛素抵抗、糖尿病与冠心病(英文)第二十页,共三十页。Baseline Anthropometric Variables and Cardiovascular Risk Baseline Anthropometric Variables and Cardiovascular Risk Factors in Subjects with Factors in Subjects with NormalNormal Glucose Tolerance at Baseline Glucose Tolerance at Baseline According to Conversion Status at 8-Year Follow-up:According to Conversion Status at 8-Year Follow-up:San Antonio San Antonio Heart StudyHeart StudyBMI(kg/m2)Centrality*TG(mmol)HDLC(mmol)SBP(mmHg)Fasting glucose(mmol)Fasting insulin(pmol)Haffner SM et al.JAMA 1990;263:2893-2898.28.2+1.11.38+0.091.83+0.121.14+0.07116.8+3.05.28+0.1157+2727.2+0.21.16+0.21.26+0.101.28+0.02108.8+0.85.00+0.0281+5.472.472.006.045.004.032.006Conversion Status at Follow-upDiabetes(n=18)Diabetes(n=18)Normal(n=490)Normal(n=490)P P*Ratio of subscapular to triceps skinfolds辨崇雷敷郭篙痘髓蒸退榴淫袭席脱龟宽苯搬匡获顾僧吐菊儒忽坎迎止悉朵胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第二十一页,共三十页。“Ticking Clock”HypothesisWHO.Diabetologia 1985;28:615-640;Haffner SM et al.JAMA 1990;263:2893-2898.ForForMicrovascular Microvascular complicationscomplicationsMacrovascular Macrovascular complicationscomplicationsThe“clock starts ticking”The“clock starts ticking”At onset of hyperglycemiaAt onset of hyperglycemiaBefore the diagnosis of Before the diagnosis of hyperglycemiahyperglycemia淌郝古凸孽敦汕嫁郎习有奶榴荔瞳狈绦筒优贷忻改挽莆薪颐过殉侦阅烛排胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第二十二页,共三十页。Hemoglobin AHemoglobin A1 1Fasting GlucoseFasting GlucoseThe 7-Year Age-Adjusted Incidence of CHD Mortality and All CHD Events:East-West StudyLehto S et al.Diabetes 1997;46:1354-1359.403020100%IncidenceP-glucose(mmol/L)13.4403020100%IncidenceCHD MortalityAll CHD EventsCHD MortalityAll CHD EventsHbA1(%)10.7银迎虱稀碱揭画疼鉴采惯奏试骇骆柞杨捻匀嗅篷睬山造臣菠歇党瞻芦鱼胖胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第二十三页,共三十页。Stepwise Selection of Risk Factors*in 2693 White Stepwise Selection of Risk Factors*in 2693 White Patients with Type 2 Diabetes with Dependent Variable Patients with Type 2 Diabetes with Dependent Variable as Time to First Event:as Time to First Event:UKPDSUKPDS VariableVariableLow-Density Lipoprotein CholesterolHigh-Density Lipoprotein CholesterolHemoglobin A1cSystolic Blood PressureSmokingP ValueP Value0.0001 0.0001 0.0022 0.00650.056Coronary Artery Disease(n=280)Position in ModelPosition in ModelFirstSecondThirdFourthFifth*Adjusted for age and sex.Turner RC et al.BMJ 1998;316:823-828.哑颂撒挑茨耘茸趁伤装竖靛司溢咒许枷欠仁繁遣丈哥锹敞律堂郁蝴辖丙耘胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第二十四页,共三十页。Criteria for Accepting Cardiovascular Risk Factor Criteria for Accepting Cardiovascular Risk Factor Management as Similar in Diabetic and CHD Management as Similar in Diabetic and CHD SubjectsSubjectsnThe risk of vascular disease is similar in diabetic subjects without pre-existing vascular disease as in nondiabetic subjects with vascular diseasenGlycemia alone will not completely eliminate the excess of CHD risk in diabetic subjectsnLipid interventions to reduce CHD can be equally effective in diabetic and nondiabetic subjects屁倡梆未红俏般砒萄属耗躇轻宗属弟河椰氏痉几恩锨以榴茄唬挡篆木耀泼胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第二十五页,共三十页。Incidence of Fatal or Nonfatal MI During a 7-Year Incidence of Fatal or Nonfatal MI During a 7-Year Follow-up in Relation to History of MI in Nondiabetic Follow-up in Relation to History of MI in Nondiabetic vs Diabetic Subjects:vs Diabetic Subjects:East-West StudyEast-West StudyIncidence During Follow-up(%)(n=69)Nondiabetics with prior MINondiabetics with no prior MIDiabetics with prior MIDiabetics with no prior MI18.8Haffner SM et al.N Engl J Med 1998;339:229-234.(n=1304)(n=169)(n=890)3.00.57.83.23.545.020.2Events per100 person-yr:P0.001p0.001竖竿亚憾度啤副冻猩鸽价椒类涤驻康遂猴放蹋橇倔卢组捉萌予菠三舶讳宫胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)胰岛素抵抗(d k n g)、糖尿病与冠心病(英文)第二十六页,共三十页。Incidence of Fatal or Nonfatal Stroke During a Incidence of Fatal or Nonfatal Stroke During a 7-Year Follow-up in Relation to History of MI in Nondiabetic 7-Year Follow-up in Relation to History of MI in Nondiabetic vs Diabetic Subjects:vs Diabetic Subjects:East-West StudyEast-West StudyIncidence During Follow-up(%)(n=69)Nondiabetics with prior MINondiabetics with no prior MIDiabetics with prior MIDiabetics with no prior MI7.2Haffner SM et al.N Engl J Med 1998;339:229-234.(n=1304)(n=169)(n=890)1.20.33.41.61.919.510.3Events per100 person-yr:P=0.01p11.1(200)。Otherheartdisease第三十页,共三十页。- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 精品 医学 专题 胰岛素 抵抗 糖尿病 冠心病 英文
咨信网温馨提示:
1、咨信平台为文档C2C交易模式,即用户上传的文档直接被用户下载,收益归上传人(含作者)所有;本站仅是提供信息存储空间和展示预览,仅对用户上传内容的表现方式做保护处理,对上载内容不做任何修改或编辑。所展示的作品文档包括内容和图片全部来源于网络用户和作者上传投稿,我们不确定上传用户享有完全著作权,根据《信息网络传播权保护条例》,如果侵犯了您的版权、权益或隐私,请联系我们,核实后会尽快下架及时删除,并可随时和客服了解处理情况,尊重保护知识产权我们共同努力。
2、文档的总页数、文档格式和文档大小以系统显示为准(内容中显示的页数不一定正确),网站客服只以系统显示的页数、文件格式、文档大小作为仲裁依据,个别因单元格分列造成显示页码不一将协商解决,平台无法对文档的真实性、完整性、权威性、准确性、专业性及其观点立场做任何保证或承诺,下载前须认真查看,确认无误后再购买,务必慎重购买;若有违法违纪将进行移交司法处理,若涉侵权平台将进行基本处罚并下架。
3、本站所有内容均由用户上传,付费前请自行鉴别,如您付费,意味着您已接受本站规则且自行承担风险,本站不进行额外附加服务,虚拟产品一经售出概不退款(未进行购买下载可退充值款),文档一经付费(服务费)、不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
4、如你看到网页展示的文档有www.zixin.com.cn水印,是因预览和防盗链等技术需要对页面进行转换压缩成图而已,我们并不对上传的文档进行任何编辑或修改,文档下载后都不会有水印标识(原文档上传前个别存留的除外),下载后原文更清晰;试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓;PPT和DOC文档可被视为“模板”,允许上传人保留章节、目录结构的情况下删减部份的内容;PDF文档不管是原文档转换或图片扫描而得,本站不作要求视为允许,下载前自行私信或留言给上传者【Fis****915】。
5、本文档所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用;网站提供的党政主题相关内容(国旗、国徽、党徽--等)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
6、文档遇到问题,请及时私信或留言给本站上传会员【Fis****915】,需本站解决可联系【 微信客服】、【 QQ客服】,若有其他问题请点击或扫码反馈【 服务填表】;文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“【 版权申诉】”(推荐),意见反馈和侵权处理邮箱:1219186828@qq.com;也可以拔打客服电话:4008-655-100;投诉/维权电话:4009-655-100。
1、咨信平台为文档C2C交易模式,即用户上传的文档直接被用户下载,收益归上传人(含作者)所有;本站仅是提供信息存储空间和展示预览,仅对用户上传内容的表现方式做保护处理,对上载内容不做任何修改或编辑。所展示的作品文档包括内容和图片全部来源于网络用户和作者上传投稿,我们不确定上传用户享有完全著作权,根据《信息网络传播权保护条例》,如果侵犯了您的版权、权益或隐私,请联系我们,核实后会尽快下架及时删除,并可随时和客服了解处理情况,尊重保护知识产权我们共同努力。
2、文档的总页数、文档格式和文档大小以系统显示为准(内容中显示的页数不一定正确),网站客服只以系统显示的页数、文件格式、文档大小作为仲裁依据,个别因单元格分列造成显示页码不一将协商解决,平台无法对文档的真实性、完整性、权威性、准确性、专业性及其观点立场做任何保证或承诺,下载前须认真查看,确认无误后再购买,务必慎重购买;若有违法违纪将进行移交司法处理,若涉侵权平台将进行基本处罚并下架。
3、本站所有内容均由用户上传,付费前请自行鉴别,如您付费,意味着您已接受本站规则且自行承担风险,本站不进行额外附加服务,虚拟产品一经售出概不退款(未进行购买下载可退充值款),文档一经付费(服务费)、不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
4、如你看到网页展示的文档有www.zixin.com.cn水印,是因预览和防盗链等技术需要对页面进行转换压缩成图而已,我们并不对上传的文档进行任何编辑或修改,文档下载后都不会有水印标识(原文档上传前个别存留的除外),下载后原文更清晰;试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓;PPT和DOC文档可被视为“模板”,允许上传人保留章节、目录结构的情况下删减部份的内容;PDF文档不管是原文档转换或图片扫描而得,本站不作要求视为允许,下载前自行私信或留言给上传者【Fis****915】。
5、本文档所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用;网站提供的党政主题相关内容(国旗、国徽、党徽--等)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。
6、文档遇到问题,请及时私信或留言给本站上传会员【Fis****915】,需本站解决可联系【 微信客服】、【 QQ客服】,若有其他问题请点击或扫码反馈【 服务填表】;文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“【 版权申诉】”(推荐),意见反馈和侵权处理邮箱:1219186828@qq.com;也可以拔打客服电话:4008-655-100;投诉/维权电话:4009-655-100。
关于本文